Lidocaine 5% transdermal patch

Core Technical SpecificationsActive Ingredient: Lidocaine (5% w/w). Each individual patch contains 700 mg of lidocaine (50 mg per gram of aqueous adhesive base). Primary Clinical Indications: Post-Herpetic Neuralgia (PHN): Officially FDA-approved for relieving localized nerve pain secondary to previous herpes zoster (shingles) infections. Targeted Nerve Stabilization: Blocks voltage-gated sodium channels on damaged pain fibers directly under the patch to prevent aberrant pain signals from reaching the brain. Allodynia Barrier: Provides a physical layer of protection, preventing standard clothing friction from triggering intense nerve pain responses.